Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTAI BioXcel Therapeutics	$5.00 -4.3%	$2.62	$1.17 ▼ $13.36	$30.18M	0.05	5.08 million shs	3.53 million shs
MTNB Matinas Biopharma	$2.06 +18.4%	$1.08	$0.47 ▼ $5.24	$10.53M	1.32	448,341 shs	289,547 shs
MURA Mural Oncology	$2.08 +0.2%	$2.27	$0.95 ▼ $4.74	$35.95M	3	1.99 million shs	376,885 shs
SNYR Synergy CHC	$2.93 +1.0%	$3.22	$1.19 ▼ $10.00	$27.67M	N/A	460,428 shs	72,809 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTAI BioXcel Therapeutics	+3.77%	+10.11%	+189.75%	+276.26%	-51.97%
MTNB Matinas Biopharma	0.00%	+5.45%	+83.12%	+114.29%	+837.00%
MURA Mural Oncology	-0.96%	+16.95%	-15.51%	-24.73%	-37.08%
SNYR Synergy CHC	+1.40%	-18.31%	-18.54%	+47.96%	+9,566.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTAI BioXcel Therapeutics	4.5375 of 5 stars	3.4	5.0	4.5	3.1	1.7	0.6
MTNB Matinas Biopharma	1.3521 of 5 stars	0.0	5.0	0.0	3.3	0.0	0.6
MURA Mural Oncology	2.9618 of 5 stars	3.3	3.0	0.0	1.8	2.5	1.3
SNYR Synergy CHC	4.34 of 5 stars	3.8	0.0	0.0	2.9	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTAI BioXcel Therapeutics	2.80	Moderate Buy	$39.75	694.36% Upside
MTNB Matinas Biopharma	2.00	Hold	N/A	N/A
MURA Mural Oncology	2.50	Moderate Buy	$12.00	478.31% Upside
SNYR Synergy CHC	3.50	Strong Buy	$10.00	241.30% Upside

Current Analyst Ratings Breakdown

Latest MTNB, SNYR, MURA, and BTAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/15/2025	BTAI BioXcel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTAI BioXcel Therapeutics	$2.27M	13.36	N/A	N/A	($17.78) per share	-0.28
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	$4.43 per share	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	$3.39 per share	N/A
SNYR Synergy CHC	$33.70M	0.82	$0.27 per share	10.73	($1.31) per share	-2.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTAI BioXcel Therapeutics	-$59.60M	-$12.64	N/A	N/A	N/A	-5,869.82%	N/A	-134.45%	N/A
MTNB Matinas Biopharma	-$22.94M	-$3.89	N/A	∞	N/A	N/A	-123.06%	-94.28%	N/A
MURA Mural Oncology	-$128.51M	-$8.59	N/A	N/A	N/A	N/A	-107.76%	-87.57%	N/A
SNYR Synergy CHC	$2.12M	$0.38	7.71	4.97	N/A	10.02%	-18.56%	20.28%	N/A

Latest MTNB, SNYR, MURA, and BTAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SNYR Synergy CHC	$0.08	$0.17	+$0.09	$0.17	$10.80 million	$6.74 million
8/12/2025	Q2 2025	BTAI BioXcel Therapeutics	-$2.30	-$2.45	-$0.15	-$2.45	$0.21 million	$0.12 million
8/4/2025	Q2 2025	MURA Mural Oncology	-$1.13	-$1.77	-$0.64	-$2.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTAI BioXcel Therapeutics	N/A	0.76	0.74
MTNB Matinas Biopharma	N/A	5.53	5.53
MURA Mural Oncology	N/A	2.87	2.87
SNYR Synergy CHC	N/A	2.74	1.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTAI BioXcel Therapeutics	30.68%
MTNB Matinas Biopharma	11.77%
MURA Mural Oncology	80.21%
SNYR Synergy CHC	N/A

Insider Ownership

Company	Insider Ownership
BTAI BioXcel Therapeutics	21.20%
MTNB Matinas Biopharma	4.60%
MURA Mural Oncology	2.20%
SNYR Synergy CHC	56.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTAI BioXcel Therapeutics	90	6.06 million	4.77 million	Optionable
MTNB Matinas Biopharma	30	5.09 million	4.60 million	N/A
MURA Mural Oncology	119	17.32 million	16.94 million	Optionable
SNYR Synergy CHC	40	9.44 million	4.10 million	N/A

MTNB, SNYR, MURA, and BTAI Headlines

Recent News About These Companies

Synergy CHC's (NASDAQ:SNYR) Earnings Quality Is Low

August 22 at 10:03 AM | finance.yahoo.com

Synergy CHC Corp to Present at the 2025 Gateway Conference on September 4th

August 21 at 9:40 AM | markets.businessinsider.com

New to The Street’s Esteemed Client Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor(R) Focus + Energy EG America, 6th Largest U.S ...

August 20 at 6:38 PM | palmbeachpost.comP

Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor® Focus + Energy

August 18, 2025 | taiwannews.com.twT

New to The Street's Esteemed Client Synergy CHC Corp. Announces Nationwide EG America Rollout for FOCUSfactor Focus + Energy EG America, 6th Largest U.S. Convenience Chain ...

August 18, 2025 | finanznachrichten.de

Synergy CHC announces major distribution with for FOCUSfactor Focus + Energy

August 18, 2025 | msn.com

Synergy CHC Expands FOCUSfactor Distribution with EG America

August 18, 2025 | tipranks.com

Analysts Set Expectations for Synergy CHC FY2025 Earnings

August 18, 2025 | americanbankingnews.com

Synergy CHC files to sell 1.28M shares of common stock

August 15, 2025 | msn.com

Synergy Chc EPS Jumps 86 Percent in Q2

August 15, 2025 | theglobeandmail.com

Synergy CHC Corp.: Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability

August 14, 2025 | finanznachrichten.de

Synergy CHC reports Q2 EPS 17c vs 9c last year

August 14, 2025 | msn.com

Synergy CHC Corp. Reports Strong Second Quarter 2025 Financial Results with Significant Year-over-Year Growth

August 14, 2025 | quiverquant.comQ

Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability

August 14, 2025 | globenewswire.com

New to The Street TV Commercial Campaigns Achieve Millions of Views with 87% Average Completion Rate

August 5, 2025 | indystar.comI

New to The Street Launches 1,000+ Commercial TV Blitz for Synergy CHC ($SNYR), Makers of Focus Factor(R) – Adds NewsOut Video PR Coverage & NYC #1 Market Saturation

August 5, 2025 | desmoinesregister.comD

Jack Ross Buys Handful Of Shares In Synergy CHC

August 3, 2025 | finance.yahoo.com

Insider Buying: Synergy CHC Corp. (NASDAQ:SNYR) CEO Purchases 3,750 Shares of Stock

August 1, 2025 | insidertrades.com

Synergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call Information

July 31, 2025 | manilatimes.netM

Synergy CHC Corp. Stock (SNYR) Opinions on Retail Distribution Expansion

July 31, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTNB, SNYR, MURA, and BTAI Company Descriptions

BioXcel Therapeutics NASDAQ:BTAI

$5.00 -0.23 (-4.32%)

As of 03:48 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Matinas Biopharma NYSE:MTNB

$2.06 +0.32 (+18.39%)

As of 03:47 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Mural Oncology NASDAQ:MURA

$2.08 +0.01 (+0.24%)

As of 03:47 PM Eastern

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

Synergy CHC NASDAQ:SNYR

$2.93 +0.03 (+1.03%)

As of 03:24 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time